CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 120 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02390531
NCT02390531Phase 1Completed
CompareCT.gov

Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

Jaeb Center for Health Research·interventional·Posted Mar 17, 2015·Updated Nov 3, 2022

In Brief

A Phase 1 clinical trial evaluating Bevacizumab for Retinopathy of Prematurity. Completed, enrolled 120 participants across 11 sites.

Detailed Summary

The purpose of this study is to find a dose of intravitreal bevacizumab that is lower than currently used for severe retinopathy of prematurity (ROP), is effective in this study, and can be tested in future larger studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinopathy of Prematurity
CountriesUnited States
CollaboratorsPediatric Eye Disease Investigator Group, National Eye Institute (NEI)

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartApr 28, 2015
Primary CompletionJun 4, 2019
Study CompletionMay 11, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.3 years ago

Interventions

Bevacizumabdrug

Varying dosages in 10µl